From: Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Mutation | Number of patients (n, %) | % of subpopulation |
---|---|---|
BRAF | 87 (40.1) | BRAF (n = 87) |
 V600E | 63 (29.0) | 72.4 |
 V600K | 15 (6.9) | 17.2 |
 V600R | 4 (1.8) | 4.6 |
 K601E | 2 (0.9) | 2.3 |
 L597S | 1 (0.5) | 1.1 |
 V600E, K601E | 1 (0.5) | 1.1 |
 A598A, R603* | 1 (0.5) | 1.1 |
NRAS | 53 (24.4) | NRAS (n = 53) |
 Q61K | 22 (10.1) | 41.5 |
 Q61R | 19 (8.8) | 35.8 |
 Q61L | 3 (1.4) | 5.7 |
 Q61V | 1 (0.5) | 1.9 |
 Q61H | 1 (0.5) | 1.9 |
 A59D | 2 (0.9) | 3.8 |
 G12D | 1 (0.5) | 1.9 |
 G13R | 2 (0.9) | 3.8 |
BRAF + NRAS | 5 (2.3) | BRAF + NRAS (n = 5) |
 V600E, Q61K | 1 (0.5) | 20.0 |
 V600E, Q61L | 1 (0.5) | 20.0 |
 V600E, G12S | 1 (0.5) | 20.0 |
 K601E, Q61L | 1 (0.5) | 20.0 |
 L584F, Q61K | 1 (0.5) | 20.0 |